Expression of KISS1 and KISS1R (GPR54) may be used as favorable prognostic markers for patients with non-small cell lung cancer

Abstract

Lung cancer is the most commonly diagnosed cancer worldwide. Loss of KISS1 expression has been associated with progression and poor prognosis of various cancers, however, the precise role of KISS1 expression in non-small cell lung cancer (NSCLC) is not well defined. KISS1 receptor (KISS1R, also named GPR54) coupled to KISS1, has been shown to play a pivotal role in suppressing cancer metastasis. In this study, 56 NSCLC specimens were divided into stage IIIB (locally advanced) and stage IV (metastatic). The mRNA and protein levels of KISS1 and KISS1R in cancer tissues were found to be lower compared to that in normal tissues using RT-PCR and western blot analysis, respectively. In addition, the expression of both KISS1 and KISS1R in stage IV NSCLC was lower compared to that in stage IIIB stage NSCLC. The cumulative survival rate of the patients with KISS1 or KISS1R expression was significantly higher compared to that without expression. KISS1 or KISS1R expression in NSCLC can be used to indicate favorable prognosis for disease outcome. Metastin, the product of the KISS1 gene, was lower in the serum of patients with stage IV NSCLC compared to that in stage IIIB NSCLC.

Association of chromosome 19 to lung cancer genotypes and phenotypes

“…In a study of 56 NSCLC cases, the KISS1 or KISS1R low expression was significantly associated with poor overall survival. The product of the metastin, was also lower in the serum of patients with stage IV NSCLC compared to that in stage IIIB NSCLC [51]. The metastasis suppressing properties may be mediated in part by cell cycle arrest and induction of apoptosis in lung cancer.…”

Kiss1R Identification and Biodistribution Analysis Employing a Western Ligand Blot and Ligand‐Derivative Stain with a FITC‐Kisspeptin Derivative

“…A previous study has shown that Kiss1R expression correlates with tumor progression and a poor patient prognosis. [14] Characterization of the expression of Kiss1R in tumors would be valuable for prognoses. However, production of an antibody that binds to Kiss1R has not been achieved.…”

Evaluation of KiSS1 as a Prognostic Biomarker in North Indian Breast Cancer Cases

“…Off late KiSS1 has been shown to be epigenetically silenced by hypermethylation in bladder cancer (Cebrian et al, 2011) and colorectal cancer (Moya et al, 2013). Data amassed from the literature support the hypothesis that loss of KiSS1 expression has been associated with the progression and metastasis of various tumors, including esophageal, brain, ovarian and melanoma (Li et al, 2012;Sun et al, 2013;Okugawa et al, 2013). Expression of KiSS1 like other MSGs is commonly reduced or completely absent in a variety of cancers via an unknown mechanism (Mitchell et al, 2007).…”

“…KiSS1 has been evaluated in a number of cancers like colon, gastric, prostate, lung (Dhar et al, 2004;Schumacher et al, 2007;Sasaki et al, 2008;Li et al, 2012;Sun et al, 2013), not much literature is available on Indian population. The clinicopathological parameters have not been studied in detail in a single population in context to associating with metastatic markers and metastatic propensity.…”